Beneficial Ownership Report · SCHEDULE 13G
ADARx Pharmaceuticals, Inc.
ADRXNASDAQEQUITYCurrent
Beneficial Ownership Report
Structured filing — SCHEDULE 13G
primary_doc.xml
Subject company
- Company
- ADARx Pharmaceuticals, Inc.
- Company CIK
- 0001802369
- Street
- 5871 Oberlin Drive
- Street (continued)
- Suite 200
- City
- San Diego
- State / country code
- CA
- Postal code
- 92121
Statement details
- Security class
- Common Stock, $0.0001 par value per share
- Event date
- 09/24/2026
- Rule designation
- Rule 13d-1(c)
Reporting person 1
- Name
- BCLS Fund III Investments, LP
- Citizenship / organization
- DE
- Reporting person type
- PN
- Aggregate amount owned
- 6,728,970
- Percent of class
- 6.30
- Sole voting power
- 0
- Shared voting power
- 6,728,970
- Sole dispositive power
- 0
- Shared dispositive power
- 6,728,970
- Aggregate excludes certain shares
- N
Item 1
Issuer
ADARx Pharmaceuticals, Inc.
Principal executive office address
5871 Oberlin Drive, Suite 200, San Diego, California 92121.
Item 2
Citizenship
Each of the Bain Capital Life Sciences Entities is organized under the laws of the State of Delaware.
Filing person
This Schedule 13G is being filed by BCLS Fund III Investments, LP, a Delaware limited partnership (the "Reporting Person"). Bain Capital Life Sciences Investors, LLC, a Delaware limited liability company ("BCLSI"), is the manager of Bain Capital Life Sciences III General Partner, LLC, a Delaware limited liability company ("BCLS Fund III GP"), which is the general partner of Bain Capital Life Sciences Fund III, L.P., a Delaware limited partnership ("BCLS Fund III"), which is the managing member of BCLS Fund III Investments GP, LLC, a Delaware limited liability company (together with the Reporting Person, BCLSI, BCLS Fund III GP and BCLS Fund III, the "Bain Capital Life Sciences Entities"), which is the general partner of the Reporting Person. As a result, BCLSI may be deemed to share voting and dispositive power with respect to the securities held by the Reporting Person.
Principal business or residence address
The principal business address for each of the Bain Capital Life Sciences Entities is 200 Clarendon Street, Boston, Massachusetts 02116.
Item 3
Not applicable indication
Y
Item 4
Percent of class
See Item 4(a) hereof.
Amount beneficially owned
As of the date hereof, the Reporting Person holds 6,728,970 shares of Common Stock, representing approximately 6.3% of the outstanding shares of Common Stock. The percentage of the outstanding shares of Common Stock held by the Reporting Person is based on 106,801,325 shares of Common Stock outstanding, as reported by the Issuer in its prospectus filed with the Securities and Exchange Commission on September 28, 2026.
Sole voting power
0
Shared voting power
6,728,970
Sole dispositive power
0
Shared dispositive power
6,728,970
Item 5
Not applicable indication
Y
Item 6
Not applicable indication
Y
Item 7
Not applicable indication
Y
Item 8
Not applicable indication
Y
Item 9
Not applicable indication
Y
Item 10
Not applicable indication
N
Certifications
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
Signature 1
- Reporting person
- BCLS Fund III Investments, LP
- Signed
- /s/ Ricky Sun
- Title
- Ricky Sun, Partner of Bain Capital Life Sciences Investors, LLC
- Date
- 10/01/2026
Company context
We are a late-clinical stage biotechnology company focused on developing next-generation siRNA therapeutics designed to treat a broad spectrum of diseases. We are focused on advancing and expanding our pipeline of highly potent, selective and durable siRNA therapeutic candidates, including three clinical-stage programs and two advanced preclinical programs. Our goal is to control the expression of specific disease drivers with highly selective RNA targeted therapies, delivering life-changing treatments for patients with urgent unmet medical needs. Our team is united by a shared vision to build a leading next-generation siRNA therapeutics company.